Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
61.62
+0.01 (0.02%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.94 - 62.28
52 week 54.98 - 135.59
Open 62.05
Vol / Avg. 1.24M/702,844.00
Mkt cap 1.55B
P/E     -
Div/yield     -
EPS -14.80
Shares 25.10M
Beta -2.08
Inst. own 79%
Feb 21, 2018
Q4 2017 Intercept Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 14, 2017
Intercept Pharmaceuticals Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Nov 7, 2017
Intercept Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Webcast
Nov 1, 2017
Q3 2017 Intercept Pharmaceuticals Inc Earnings Release
Nov 1, 2017
Q3 2017 Intercept Pharmaceuticals Inc Earnings Call - Webcast
Sep 25, 2017
Intercept Pharmaceuticals Statement Regarding Ocaliva� Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients - Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -175.64% -1654.56%
Operating margin -160.09% -1613.31%
EBITD margin - -1417.61%
Return on average assets -49.52% -59.19%
Return on average equity -206.99% -90.03%
Employees 456 -
CDP Score - -

Address

10 Hudson Yards Fl 37
NEW YORK, NY 10001-2160
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Officers and directors

Paolo Fundaro Independent Chairman of the Board
Age: 43
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Sandip S. Kapadia Chief Financial Officer, Treasurer
Age: 47
Bio & Compensation  - Reuters
Lisa Bright President, International
Age: 49
Bio & Compensation  - Reuters
Jerome Benedict Durso Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
David A Ford Chief Human Resource Officer
Bio & Compensation  - Reuters
Richard Kim Senior Vice President, Commercial U.S.
Age: 48
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Business and Strategy Officer
Age: 44
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D. Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters